INNOPPMED

Innoppmed is a South Korean biotechnology company focused on the development of precision medicines through an AI-integrated drug discovery platform. The company's primary research efforts are directed toward oncology, specifically targeting the TAM receptor family (AXL, MERTK, TYRO3) to overcome drug resistance in solid tumors. Innoppmed utilizes its proprietary computational tools to optimize small molecule inhibitors with high selectivity and potency. Their lead candidate, IPM-101, is being developed for the treatment of non-small cell lung cancer and other advanced malignancies. By combining bioinformatics with experimental validation, the company aims to address significant unmet needs in the treatment of cancer and inflammatory disorders. The company's approach integrates deep learning and structure-based drug design to accelerate the identification of novel therapeutic candidates.